May 29, 2012Open Access
View Full PaperMid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea
Structured PICO
Does MR-proANP and MR-proADM testing improve the diagnostic and prognostic evaluation in patients with acute dyspnoea?
P
Population
patients with acute dyspnoea
I
Intervention
Mid-regional pro-atrial natriuretic peptide (MR-proANP) and pro-adrenomedullin (MR-proADM) testing
O
Outcome
diagnosis of acute decompensated heart failure (ADHF) and prognosis
MR-proANP and MR-proADM testing provides diagnostic accuracy for ADHF and independent prognostic value up to 4 years in patients presenting with acute dyspnea.
Abstract
Among patients with acute dyspnoea, MR-proANP is accurate for diagnosis of ADHF, while both MR-proANP and MR-proADM are independently prognostic to 4 years of the follow-up.